Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study

INTRODUCTION: Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the large intestine. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23 and has proven efficacy in inducing and maintaining remission in adult patients with moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Katsuyoshi, Nagano, Katsumasa, Nagasaki, Shinya, Murata, Yoko, Hisamatsu, Tadakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073412/
https://www.ncbi.nlm.nih.gov/pubmed/35508346
http://dx.doi.org/10.1136/bmjopen-2021-060081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073412/
https://www.ncbi.nlm.nih.gov/pubmed/35508346
http://dx.doi.org/10.1136/bmjopen-2021-060081

Ejemplares similares